On January 2, 2025, China's NMPA approved its first-ever mesenchymal stem cell therapy. Here's what the science actually says — and what it means for patients.
On January 2, 2025, China's National Medical Products Administration (NMPA) granted conditional marketing authorization to amimestrocel injection — brand name Ruibosheng — making it the country's first officially approved human umbilical cord mesenchymal stem cell (MSC) therapy.
A Historic Milestone in Chinese Medicine
On January 2, 2025, China's National Medical Products Administration (NMPA) granted conditional marketing authorization to amimestrocel injection — brand name Ruibosheng — making it the country's first officially approved human umbilical cord mesenchymal stem cell (MSC) therapy.
This isn't a clinical trial. It's a fully regulated, commercially authorized drug, now available through licensed Chinese hospitals. For international patients considering stem cell treatment in China, understanding what this approval means — and what it doesn't — is essential.
What Is Amimestrocel (Ruibosheng)?
Amimestrocel is derived from human umbilical cord mesenchymal stem cells (hUC-MSCs). The product is manufactured by Platinum Life, a domestic Chinese biopharmaceutical company, under Good Manufacturing Practice (GMP) conditions.
Approved indication: Steroid-refractory acute graft-versus-host disease (aGVHD) in patients aged 14 and older. aGVHD is a life-threatening immune complication that can occur after bone marrow transplantation.
The conditional approval pathway — similar to the FDA's Accelerated Approval — requires the manufacturer to submit further confirmatory trial data post-market.
What the Research Shows
The approval was backed by clinical data demonstrating meaningful responses in patients who had already failed steroid treatment — historically a population with very poor outcomes. Published literature on hUC-MSC therapy for aGVHD (across multiple studies globally) has shown:
- Overall response rates of 60–80% in steroid-refractory aGVHD patients
- Favorable safety profile with no major concerns around tumor formation or immune rejection
- Durable responses in a subset of patients at 6–12 month follow-up
The NMPA's decision follows similar approvals in Japan and South Korea for MSC-based therapies in comparable indications.
Why This Matters Beyond aGVHD
The approval of Ruibosheng signals a regulatory shift. After years of running clinical trials, China now has a formal approval pathway for cell therapies — and the pipeline is large. As of 2024, China had registered 2,794 total cell therapy clinical trials since 2005, with 61 new trials registered under the CDE formal system in 2023 alone, and a further 42% surge in 2024.
MSC therapies are being actively trialed in China for conditions including:
- Autoimmune diseases (lupus, rheumatoid arthritis, Crohn's disease)
- Neurological conditions (Parkinson's disease, ALS)
- Orthopedic indications (cartilage regeneration, osteoarthritis)
- Pulmonary fibrosis and other inflammatory conditions
What International Patients Should Understand
The NMPA-approved Ruibosheng product is authorized specifically for aGVHD. Treatments for other conditions using MSCs in China are conducted within registered clinical trials — not as commercial therapies. Legitimate hospitals do not charge patients for unapproved experimental treatments outside of clinical trial frameworks.
If you are considering MSC therapy in China for any condition, ask the hospital:
- Is this treatment approved by the NMPA, or conducted within a registered clinical trial?
- What is the trial registration number (CDE or WHO ICTRP)?
- What is the published data on outcomes for my specific condition?
How to Access Legitimate Treatment
Panda Touring Care works exclusively with Class A tertiary hospitals and licensed research centers operating within China's regulatory framework. We can connect you with centers running NMPA-registered clinical trials and, where applicable, access to the newly approved commercial MSC therapy for eligible aGVHD patients.
Source: NMPA official announcement, January 2025 (english.nmpa.gov.cn); BioInformant, January 2025; Journal of Hematology & Oncology, October 2024 (PMC11476068).